The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Running trials

• Enrolling by invitation

  Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms

  NCT07619417· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients

  NCT06424522· Ohio State University Comprehensive Cancer Center· Source

• Not yet recruiting

  Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

  NCT07217990· Phase 1/2· Ohio State University Comprehensive Cancer Center· Source

• Not yet recruiting

  Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma

  NCT07874347· Phase 1/2· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

  NCT06930352· Phase 2· Uma Borate· Source

• Recruiting

  A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors

  NCT07699991· Ohio State University Comprehensive Cancer Center· Source

• Not yet recruiting

  Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall

  NCT07823491· Phase 3· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma

  NCT07676877· Phase 1· Nathan Denlinger· Source

• Recruiting

  Prospective Multiomic Analysis in Small-Cell Lung Cancer

  NCT07795411· Ohio State University Comprehensive Cancer Center· Source

• Not yet recruiting

  Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital

  NCT07606287· Ohio State University Comprehensive Cancer Center· Source

• Not yet recruiting

  Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients

  NCT07594678· Phase 2· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma

  NCT07780838· Phase 2· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT07557056· Phase 2· Jennifer Woyach· Source

• Recruiting

  A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  NCT07293247· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Not yet recruiting

  Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial

  NCT07723235· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

  NCT07705919· Phase 1/2· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  NCT06917911· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  NCT07437950· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial

  NCT07746388· Phase 2· University of Maryland, Baltimore· Source

• Recruiting

  Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

  NCT07734038· Phase 2· Kerry Rogers· Source

• Not yet recruiting

  Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

  NCT06816979· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Impact of Novel vs. Usual Brand Menthol Cigarettes on Abuse Liability

  NCT07564648· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Prehabilitation Physical Therapy and Relaxation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery, ROAR-LCS Trial

  NCT07584239· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

  NCT07657312· Phase 2· Naresh Bumma· Source

• Recruiting

  Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia

  NCT07685717· Phase 2· Jennifer Woyach· Source

• Recruiting

  Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

  NCT07003295· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

  NCT06741072· Phase 1· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

  NCT05521698· Phase 1· University of Wisconsin, Madison· Source

• Recruiting

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

  NCT07012031· Phase 1/2· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

  NCT07061951· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms

  NCT07529483· Phase 2· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  NCT07321652· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

  NCT07609030· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  NCT07342478· Phase 3· Newave Pharmaceutical Inc· Source

• Recruiting

  A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

  NCT07271667· Phase 2· Curis, Inc.· Source

• Recruiting

  Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

  NCT07068074· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

  NCT07423585· Phase 2· Asrar Alahmadi· Source

• Recruiting

  Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

  NCT06863311· Phase 2· Karie Runcie· Source

• Recruiting

  Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

  NCT07407647· Phase 2· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer

  NCT07619391· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

  NCT07144826· Early phase 1· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

  NCT07166406· Phase 3· NRG Oncology· Source

• Recruiting

  Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

  NCT07474519· Phase 4· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

  NCT06900595· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

  NCT07356245· Phase 2· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  NCT07280013· Phase 1· C4 Therapeutics, Inc.· Source

• Recruiting

  Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study

  NCT07215988· Ohio State University Comprehensive Cancer Center· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

Showing 50 of 491.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer34 recruiting
• Chronic lymphocytic leukaemia21 recruiting
• Childhood cancers17 recruiting
• Colorectal cancer17 recruiting
• Pancreatic cancer17 recruiting
• Acute myeloid leukaemia13 recruiting
• Metastatic breast cancer13 recruiting
• Bladder cancer12 recruiting
• Ovarian cancer12 recruiting
• Melanoma11 recruiting
• Prostate cancer11 recruiting
• Diffuse large B-cell lymphoma9 recruiting
• Head and neck cancer9 recruiting
• Kidney cancer9 recruiting
• Myelodysplastic syndromes9 recruiting
• Neuroendocrine tumours9 recruiting
• Triple-negative breast cancer9 recruiting
• Acute lymphoblastic leukaemia8 recruiting
• Multiple myeloma8 recruiting
• Sarcoma8 recruiting
• Myeloproliferative neoplasms7 recruiting
• Endometrial cancer6 recruiting
• Follicular lymphoma5 recruiting
• Mantle cell lymphoma5 recruiting
• Brain metastases4 recruiting
• Cervical cancer4 recruiting
• Gastric and oesophageal cancer4 recruiting
• Glioblastoma4 recruiting
• Liver and biliary tract cancer4 recruiting
• Chronic myeloid leukaemia3 recruiting
• Mesothelioma3 recruiting
• Hodgkin lymphoma2 recruiting
• Amyloidosis1 recruiting
• Burkitt lymphoma1 recruiting
• Chronic kidney disease1 recruiting
• Crohn's disease1 recruiting
• Depression1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Lupus (SLE)1 recruiting
• Meningioma1 recruiting
• Multiple sclerosis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Terminated

  Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

  NCT06714591· Phase 1· SystImmune Inc.· Source

• Completed

  Online Tai Chi Intervention to Promote Smoking Cessation Among Cancer Survivors

  NCT05941858· Ohio State University Comprehensive Cancer Center· Source

• Terminated

  Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

  NCT05554354· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy

  NCT06378398· Early phase 1· University of Michigan Rogel Cancer Center· Source

• Completed

  Evaluation of Canakinumab in High-Risk Former-Smokers

  NCT06038526· Phase 2· Peter Shields· Source

• Completed

  Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

  NCT06203912· Phase 1· Elvira Umyarova· Source

• Withdrawn

  Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung

  NCT05412875· Ohio State University Comprehensive Cancer Center· Source

• Completed

  Online Mindfulness-Based Intervention to Decrease Pre-Procedural Anxiety Before a First-Time Screening Colonoscopy

  NCT06233253· Ohio State University Comprehensive Cancer Center· Source

• Completed

  A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)

  NCT05558696· Phase 2· Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)· Source

• Completed

  Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial

  NCT06016725· Ohio State University Comprehensive Cancer Center· Source

• Terminated

  Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study

  NCT04992507· Phase 2· Ohio State University Comprehensive Cancer Center· Source

• Completed

  Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

  NCT06031194· Ohio State University Comprehensive Cancer Center· Source

• Completed

  Head and Neck Cancer Patient Symptom and Oncologic Outcomes

  NCT05243069· Ohio State University Comprehensive Cancer Center· Source

• Terminated

  A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

  NCT05514717· Phase 1· Day One Biopharmaceuticals, Inc.· Source

• Completed

  A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

  NCT05619744· Phase 1· Hoffmann-La Roche· Source

• Completed

  Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients

  NCT05716477· Ohio State University Comprehensive Cancer Center· Source

• Completed

  Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases

  NCT05503251· Phase 2· Ohio State University Comprehensive Cancer Center· Source

• Terminated

  Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

  NCT05224661· Center for International Blood and Marrow Transplant Research· Source

• Terminated

  A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

  NCT05181540· Phase 3· Angiocrine Bioscience· Source

• Completed

  Remote Assessment of Cognition, Insulin Resistance and Omega-3 Fatty Acid Biomarkers in Breast Cancer Survivors

  NCT05048108· Ohio State University Comprehensive Cancer Center· Source

• Completed

  Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

  NCT04600336· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Completed

  All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

  NCT04919369· Phase 1· Dwight Owen· Source

• Completed

  Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

  NCT04862585· Phase 2/3· Ohio State University Comprehensive Cancer Center· Source

• Completed

  Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia

  NCT04411849· Ohio State University Comprehensive Cancer Center· Source

• Terminated

  Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

  NCT04588246· Phase 3· NRG Oncology· Source

• Completed

  177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

  NCT04689828· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

  NCT05972577· Ohio State University Comprehensive Cancer Center· Source

• Terminated

  A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

  NCT04764474· Phase 1· Hutchmed· Source

• Completed

  A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

  NCT04772989· Phase 1· Arcus Biosciences, Inc.· Source

• Terminated

  Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT04852822· University of Washington· Source

• Completed

  KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

  NCT04165083· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Nipple Aspirate Fluid in Detecting Breast Cancer

  NCT03715959· Ohio State University Comprehensive Cancer Center· Source

• Completed

  Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

  NCT03641313· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT04432454· Phase 2· Sermonix Pharmaceuticals Inc.· Source

• Completed

  Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

  NCT04312841· Phase 2· Ohio State University Comprehensive Cancer Center· Source

• Completed

  The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer

  NCT04602026· Ohio State University Comprehensive Cancer Center· Source

• Completed

  Endobronchial Ultrasound-Guided Transbronchial Needle-Aspiration With Suction in Obtaining Samples From Patients With Suspected Nodal Metastatic Lung Cancer

  NCT04116970· Ohio State University Comprehensive Cancer Center· Source

• Completed

  Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

  NCT04220684· Phase 1· Sumithira Vasu· Source

• Terminated

  Continued Treatment for Participants Enrolled in Studies of BXQ-350

  NCT04404569· Phase 1· Bexion Pharmaceuticals, Inc.· Source

• Completed

  COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

  NCT04354246· Phase 1· Compugen Ltd· Source

• Terminated

  Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant

  NCT03960008· Phase 3· Lahey Clinic· Source

• Terminated

  Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

  NCT04158141· Phase 3· NRG Oncology· Source

• Completed

  KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

  NCT04165096· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

  NCT04233567· Phase 2· Sameek Roychowdhury· Source

• Terminated

  Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

  NCT04204941· Phase 1· Epizyme, Inc.· Source

• Completed

  Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

  NCT03892044· Phase 1· David Bond, MD· Source

• Completed

  Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

  NCT03801902· Phase 1· National Cancer Institute (NCI)· Source

• Completed

  Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT03781063· Phase 2· Sermonix Pharmaceuticals Inc.· Source

• Terminated

  Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

  NCT03737994· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· Phase 2· SWOG Cancer Research Network· Source

Showing 50 of 110.

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer114 works · 98 trials
• Ovarian cancer50 works · 39 trials
• Kidney cancer49 works · 21 trials
• Multiple myeloma34 works · 23 trials
• Sarcoma32 works · 28 trials
• Acute myeloid leukaemia30 works · 32 trials
• Triple-negative breast cancer28 works · 21 trials
• Endometrial cancer27 works · 22 trials
• Head and neck cancer23 works · 27 trials
• Hodgkin lymphoma23 works · 9 trials
• Chronic lymphocytic leukaemia22 works · 38 trials
• Brain metastases19 works · 15 trials
• Metastatic breast cancer13 works · 40 trials
• Neuroendocrine tumours13 works · 22 trials
• Myeloproliferative neoplasms12 works · 15 trials
• Diffuse large B-cell lymphoma11 works · 27 trials
• Mantle cell lymphoma10 works · 11 trials
• Myelodysplastic syndromes9 works · 18 trials
• Follicular lymphoma8 works · 19 trials
• Mesothelioma7 works · 6 trials